VITADIAL "Does correction of 25 OH-VITAmin D with cholecalciferol supplementation increase muscle strength in hemoDIALysis patients?": study protocol for a randomized controlled trial

Stanislas Bataille, Nathalie Pedinielli, Elisa Carreno, Mathilde Prezelin-Reydit, Philippe Chauveau, Guillaume Jean, Thomas Robert, Mickaël Bobot, Guillaume Seret, Elisabeth Jouve, Frederic Lavainne, Marianne Serveaux, Laurence Vrigneaud, Stéphanie Gentile, Stanislas Bataille, Nathalie Pedinielli, Elisa Carreno, Mathilde Prezelin-Reydit, Philippe Chauveau, Guillaume Jean, Thomas Robert, Mickaël Bobot, Guillaume Seret, Elisabeth Jouve, Frederic Lavainne, Marianne Serveaux, Laurence Vrigneaud, Stéphanie Gentile

Abstract

Background: Muscle strength decreases as kidney failure progresses. Low muscle strength affects more than 50% of hemodialysis patients and leads to daily life activities impairment. In the general population, numerous studies have linked low 25OH-vitamin D (25OHD) concentrations to the loss of the muscle strength and low physical performances. Data on native vitamin D and muscle function are scarce in the chronic kidney disease (CKD) population, but low 25OHD levels have been associated with poor muscle strength. We present in this article the protocol of an ongoing study named VITADIAL testing if cholecalciferol supplementation in hemodialysis patients with low 25OHD improves their muscle strength.

Methods/design: VITADIAL is a prospective open randomized French multicenter study. All patients will have 25OHD levels ≤50nmol/L at randomization. One group will receive 100,000 UI cholecalciferol once a month during 6 months; the other group will receive no treatment during 6 months. In order to randomize patients with 25OHD ≤50nmol/L, supplemented patients will undergo a 3 months wash-out period renewable 3 times (maximum of 12 months wash-out) until 25OHD reaches a level ≤50nmol/L. The main objective of this study is to analyze if a 6-month period of oral cholecalciferol (i.e., native vitamin D) supplementation improves muscle strength of hemodialysis patients with low 25OHD vitamin D levels. Muscle strength will be assessed at 0, 3, and 6 months, by handgrip strength measured with a quantitative dynamometer. Secondary objectives are (1) to analyze 25OHD plasma levels after vitamin D wash-out and/or supplementation, as well as factors associated with 25OHD lowering speed during wash-out, and (2) to analyze if this supplementation improves patient's autonomy, reduces frailty risk, and improves quality of life. Fifty-four patients are needed in each group to meet our main objective.

Discussion: In the general population, around 30 randomized studies analyzed the effects of vitamin D supplementation on muscle strength. These studies had very different designs, sizes, and studied population. Globally, these studies and the meta-analysis of studies favor a beneficial effect of vitamin D supplementation on muscle strength, but this effect is mainly found in the subgroup of aged patients and those with the lowest 25OHD concentrations at inclusion. We reported a positive independent association between 25OHD and handgrip strength in a population of 130 hemodialysis patients in a dose-dependent manner. In our cohort, a plateau effect was observed above 75 nmol/L. Only two randomized studies analyzed the effect of native vitamin D supplementation on muscle strength in hemodialysis patients, but unfortunately, these two studies were underpowered. VITADIAL is a trial specifically designed to assess whether cholecalciferol might benefit to hemodialysis patient's muscle strength.

Trial registration: ClinicalTrials.gov NCT04262934 . Registered on 10 February 2020 - Retrospectively registered.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Study design. 25OHD: 25-hydoxyvitamin D; VitD: Vitamin D

References

    1. Serratrice G, Toga M, Roux H, Murisasco A, de Bisschop G. Neuropathies, myopathies and neuromyopathies in chronic uremic patients. Presse Med. 1967;75:1835–1838.
    1. Painter P. Physical functioning in end-stage renal disease patients: Update 2005. Hemodial. Int. 2005;9(3):218–235. doi: 10.1111/j.1492-7535.2005.01136.x.
    1. Clyne N, Jogestrand T, Lins LE, Pehrsson SK. Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity. Nephron. 1994;67(3):322–326. doi: 10.1159/000187987.
    1. Johansen KL. Physical functioning and exercise capacity in patients on dialysis. Adv. Ren. Replace. Ther. 1999;6(2):141–148. doi: 10.1016/S1073-4449(99)70032-4.
    1. Bataille S, Serveaux M, Carreno E, Pedinielli N, Darmon P, Robert A. The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients. Clin. Nutr. 2017;36(6):1654–1660. doi: 10.1016/j.clnu.2016.10.016.
    1. Marcelli D, Usvyat LA, Kotanko P, Bayh I, Canaud B, Etter M, Gatti E, Grassmann A, Wang Y, Marelli C, Scatizzi L, Stopper A, van der Sande F, Kooman J, MONitoring Dialysis Outcomes (MONDO) Consortium Body Composition and Survival in Dialysis Patients: Results from an International Cohort Study. Clin. J. Am. Soc. Nephrol. 2015;10(7):1192–1200. doi: 10.2215/CJN.08550814.
    1. Wilkinson TJ, Gould DW, Nixon DGD, Watson EL, Smith AC. Quality over quantity? Association of skeletal muscle myosteatosis and myofibrosis on physical function in chronic kidney disease. Nephrol. Dial. Transplant. 2019;34(8):1344–1353. doi: 10.1093/ndt/gfy139.
    1. Diesel W, Emms M, Knight BK, Noakes TD, Swanepoel CR, van Zyl Smit R, Kaschula RO, Sinclair-Smith CC. Morphologic Features of the Myopathy Associated With Chronic Renal Failure. Am. J. Kidney Dis. 1993;22(5):677–684. doi: 10.1016/S0272-6386(12)80430-6.
    1. Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction: Therapy for CKD-associated muscle dysfunction. J. Cachexia Sarcopenia Muscle. 2017;8(5):735–747. doi: 10.1002/jcsm.12202.
    1. Fahal I, Bell G, Bone J, Edwards R. Physiological abnormalities of skeletal muscle in dialysis patients. Nephrol. Dial. Transplant. 1997;12(1):119–127. doi: 10.1093/ndt/12.1.119.
    1. Fahal IH. Uraemic sarcopenia: aetiology and implications. Nephrol. Dial. Transplant. 2014;29(9):1655–1665. doi: 10.1093/ndt/gft070.
    1. Bataille S, Landrier JF, Astier J, Cado S, Sallette J, Giaime P, Sampol J, Sichez H, Ollier J, Gugliotta J, Serveaux M, Cohen J, Darmon P. Haemodialysis patients with diabetes eat less than those without: A plea for a permissive diet: Dietary intakes in hemodialysis patients. Nephrology. 2017;22(9):712–719. doi: 10.1111/nep.12837.
    1. Panaye M, et al. Phenotypes influencing low physical activity in maintenance dialysis. J. Ren. Nutr. Off. J. Counc. Ren. Nutr. Natl. Kidney Found. 2015;25:31–39.
    1. Mandai S, Furukawa S, Kodaka M, Hata Y, Mori T, Nomura N, Ando F, Mori Y, Takahashi D, Yoshizaki Y, Kasagi Y, Arai Y, Sasaki E, Yoshida S, Furuichi Y, Fujii NL, Sohara E, Rai T, Uchida S. Loop diuretics affect skeletal myoblast differentiation and exercise-induced muscle hypertrophy. Sci. Rep. 2017;7(1):46369. doi: 10.1038/srep46369.
    1. Bataille S, Landrier JF, Astier J, Giaime P, Sampol J, Sichez H, Ollier J, Gugliotta J, Serveaux M, Cohen J, Darmon P. The “dose-effect” relationship between 25-hydroxyvitamin D and muscle strength in hemodialysis patients favors a normal threshold of 30 ng/mL for plasma 25-hydroxyvitamin D. J. Ren. Nutr. 2016;26(1):45–52. doi: 10.1053/j.jrn.2015.08.007.
    1. Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients. 2017;9(4). 10.3390/nu9040328.
    1. Delanaye P, et al. Native vitamin D in dialysis patients. Nephrol. Ther. 2015;11:5–15. doi: 10.1016/j.nephro.2014.10.004.
    1. Kim SM, et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J. Ren. Nutr. Off. J. Counc. Ren. Nutr. Natl. Kidney Found. 2014;24:20–25.
    1. Guessous I, et al. Comparisons of serum vitamin D levels, status, and determinants in populations with and without chronic kidney disease not requiring renal dialysis: a 24-hour urine collection population-based study. J. Ren. Nutr. Off. J. Counc. Ren. Nutr. Natl. Kidney Found. 2014;24:303–312.
    1. Jacob AI, Sallman A, Santiz Z, Hollis BW. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 1984;114(7):1313–1319. doi: 10.1093/jn/114.7.1313.
    1. Ye J-J, Zhou TB, Zhang YF, Wang Q, Su YY, Tang JM, Li HY. Levels of vitamin D receptor and CYP24A1 in patients with end-stage renal disease. Afr. Health Sci. 2016;16(2):462–467. doi: 10.4314/ahs.v16i2.14.
    1. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin. Pract. 2008;110(1):c58–c65. doi: 10.1159/000151534.
    1. Massart A, Debelle FD, Racapé J, Gervy C, Husson C, Dhaene M, Wissing KM, Nortier JL. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2014;64(5):696–705. doi: 10.1053/j.ajkd.2014.04.020.
    1. Boudville N, Inderjeeth C, Elder GJ, Glendenning P. Association between 25-hydroxyvitamin D, somatic muscle weakness and falls risk in end-stage renal failure. Clin. Endocrinol. (Oxf.) 2010;73(299–304):299–304. doi: 10.1111/j.1365-2265.2010.03821.x.
    1. Henry HL, Bouillon R, Norman AW, Gallagher JC, Lips P, Heaney RP, Vieth R, Pettifor JM, Dawson-Hughes B, Lamberg-Allardt CJ, Ebeling PR. 14th Vitamin D Workshop consensus on vitamin D nutritional guidelines. J. Steroid Biochem. Mol. Biol. 2010;121(1-2):4–6. doi: 10.1016/j.jsbmb.2010.05.008.
    1. Vernay M, Sponga M, Salanave B, Oleko A, Deschamps V, Malon A, Castetbon K Bulletin Epidémiologique Hebdomadaire, 2012, n°. 16-17, p. 189-94.
    1. Holick M, Vitamin F. D deficiency. N. Engl. J. Med. 2007;357(3):266–281. doi: 10.1056/NEJMra070553.
    1. Domingues-Faria C, Chanet A, Salles J, Berry A, Giraudet C, Patrac V, Denis P, Bouton K, Goncalves-Mendes N, Vasson MP, Boirie Y, Walrand S. Vitamin D deficiency down-regulates Notch pathway contributing to skeletal muscle atrophy in old wistar rats. Nutr. Metab. 2014;11(1):47. doi: 10.1186/1743-7075-11-47.
    1. Montenegro KR, Cruzat V, Carlessi R, Newsholme P. Mechanisms of vitamin D action in skeletal muscle. Nutr. Res. Rev. 2019;32(2):192–204. doi: 10.1017/S0954422419000064.
    1. Houston DK, Cesari M, Ferrucci L, Cherubini A, Maggio D, Bartali B, Johnson MA, Schwartz GG, Kritchevsky SB. Association between vitamin D status and physical performance: the InCHIANTI study. J. Gerontol. A. Biol. Sci. Med. Sci. 2007;62(4):440–446. doi: 10.1093/gerona/62.4.440.
    1. Gilsanz V, Kremer A, Mo AO, Wren TAL, Kremer R. Vitamin D status and its relation to muscle mass and muscle fat in young women. J. Clin. Endocrinol. Metab. 2010;95(4):1595–1601. doi: 10.1210/jc.2009-2309.
    1. Dhesi JK, Bearne LM, Moniz C, Hurley MV, Jackson SHD, Swift CG, Allain TJ. Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2002;17(5):891–897. doi: 10.1359/jbmr.2002.17.5.891.
    1. Janssen HCJP, Samson MM, Verhaar HJJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am. J. Clin. Nutr. 2002;75(4):611–615. doi: 10.1093/ajcn/75.4.611.
    1. Tagliafico AS, Ameri P, Bovio M, Puntoni M, Capaccio E, Murialdo G, Martinoli C. Relationship between fatty degeneration of thigh muscles and vitamin D status in the elderly: a preliminary MRI study. AJR Am. J. Roentgenol. 2010;194(3):728–734. doi: 10.2214/AJR.09.3130.
    1. Badsha H, Daher M, Ooi Kong K. Myalgias or non-specific muscle pain in Arab or Indo-Pakistani patients may indicate vitamin D deficiency. Clin. Rheumatol. 2009;28(8):971–973. doi: 10.1007/s10067-009-1146-7.
    1. Boyé NDA, Oudshoorn C, van der Velde N, van Lieshout EMM, de Vries OJ, Lips P, van Beeck EF, Patka P, van der Cammen TJM. Vitamin D and physical performance in older men and women visiting the emergency department because of a fall: data from the improving medication prescribing to reduce risk of falls (IMPROveFALL) study. J. Am. Geriatr. Soc. 2013;61(11):1948–1952. doi: 10.1111/jgs.12499.
    1. McBeth J, Pye SR, O'Neill TW, Macfarlane GJ, Tajar A, Bartfai G, Boonen S, Bouillon R, Casanueva F, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean MEJ, Pendleton N, Punab M, Silman AJ, Vanderschueren D, Wu FCW, EMAS Group Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study. Ann. Rheum. Dis. 2010;69(8):1448–1452. doi: 10.1136/ard.2009.116053.
    1. Beaudart C, Buckinx F, Rabenda V, Gillain S, Cavalier E, Slomian J, Petermans J, Reginster JY, Bruyère O. The effects of vitamin D on skeletal muscle strength, muscle mass, and muscle power: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 2014;99(11):4336–4345. doi: 10.1210/jc.2014-1742.
    1. Halfon M, Phan O, Teta D. Vitamin D: a review on its effects on muscle strength, the risk of fall, and frailty. BioMed Res. Int. 2015;2015(953241):1–11. doi: 10.1155/2015/953241.
    1. Ward KA, Das G, Roberts SA, Berry JL, Adams JE, Rawer R, Mughal MZ. A randomized, controlled trial of vitamin D supplementation upon musculoskeletal health in postmenarchal females. J. Clin. Endocrinol. Metab. 2010;95(10):4643–4651. doi: 10.1210/jc.2009-2725.
    1. Kenny AM, Biskup B, Robbins B, Marcella G, Burleson JA. Effects of vitamin D supplementation on strength, physical function, and health perception in older, community-dwelling men. J. Am. Geriatr. Soc. 2003;51(12):1762–1767. doi: 10.1046/j.1532-5415.2003.51561.x.
    1. Glendenning P, Zhu K, Inderjeeth C, Howat P, Lewis JR, Prince RL. Effects of three-monthly oral 150,000 IU cholecalciferol supplementation on falls, mobility, and muscle strength in older postmenopausal women: a randomized controlled trial. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2012;27(1):170–176. doi: 10.1002/jbmr.524.
    1. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004;291(16):1999–2006. doi: 10.1001/jama.291.16.1999.
    1. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018;6(11):847–858. doi: 10.1016/S2213-8587(18)30265-1.
    1. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;303(18):1815–1822. doi: 10.1001/jama.2010.594.
    1. Smith H, Anderson F, Raphael H, Maslin P, Crozier S, Cooper C. Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatol. Oxf. Engl. 2007;46(12):1852–1857. doi: 10.1093/rheumatology/kem240.
    1. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern. Med. 2016;176(2):175–183. doi: 10.1001/jamainternmed.2015.7148.
    1. Wicherts IS, van Schoor NM, Boeke AJP, Visser M, Deeg DJH, Smit J, Knol DL, Lips P. Vitamin D status predicts physical performance and its decline in older persons. J. Clin. Endocrinol. Metab. 2007;92(6):2058–2065. doi: 10.1210/jc.2006-1525.
    1. Bischoff-Ferrari H. Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary? Best Pract. Res. Clin. Rheumatol. 2009;23(6):789–795. doi: 10.1016/j.berh.2009.09.005.
    1. Ceglia L. Vitamin D and its role in skeletal muscle: Curr. Opin. Clin. Nutr. Metab. Care. 2009;12(6):628–633. doi: 10.1097/MCO.0b013e328331c707.
    1. Henderson RG, et al. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure. Lancet Lond. Engl. 1974;1:379–384. doi: 10.1016/S0140-6736(74)93149-3.
    1. Gómez-Fernández P, Sánchez Agudo L, Calatrava JM. Chronic kidney insufficiency and respiratory muscle function. Changes induced by treatment with 1,25(OH)2D3. Med. Clin. (Barc.) 1990;94:204–207.
    1. Bertoli M, Luisetto G, Arcuti V, Urso M. Uremic myopathy and calcitriol therapy in CAPD patients. ASAIO Trans. 1991;37(3):M397–M398.
    1. Wanic-Kossowska M, Grzegorzewska A, Plotast H, Bombicki K. Does calcitriol therapy improve muscle function in uremic patients. Perit. Dial. Int. J. Int. Soc. Perit. Dial. 1996;16(Suppl 1):S305–S308. doi: 10.1177/089686089601601S57.
    1. Gordon PL, Sakkas GK, Doyle JW, Shubert T, Johansen KL. Relationship between vitamin D and muscle size and strength in patients on hemodialysis. J. Ren. Nutr. Off. J. Counc. Ren. Nutr. Natl. Kidney Found. 2007;17:397–407.
    1. Franca Gois PH, Wolley M, Ranganathan D, Seguro AC. Vitamin D deficiency in chronic kidney disease: recent evidence and controversies. Int. J. Environ. Res. Public. Health. 2018;15(8). 10.3390/ijerph15081773.
    1. Marckmann P, et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 2012;27:3523–3531.
    1. Hewitt NA, O’Connor AA, O’Shaughnessy DV, Elder GJ. Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients. Clin. J. Am. Soc. Nephrol. CJASN. 2013;8(7):1143–1149. doi: 10.2215/CJN.02840312.
    1. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–423. doi: 10.1093/ageing/afq034.
    1. Matos CM, et al. Handgrip strength at baseline and mortality risk in a cohort of women and men on hemodialysis: a 4-year study. J. Ren. Nutr. Off. J. Counc. Ren. Nutr. Natl. Kidney Found. 2014;24:157–162.
    1. Katz S, Ford AB, Moskowitz RW. Jackson, B. A. & Jaffe, M. W. Studies of illness in the aged. the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185(12):914–919. doi: 10.1001/jama.1963.03060120024016.
    1. Cesari M, Demougeot L, Boccalon H, Guyonnet S, Abellan van Kan G, Vellas B, Andrieu S. A self-reported screening tool for detecting community-dwelling older persons with frailty syndrome in the absence of mobility disability: the FiND questionnaire. PloS One. 2014;9(7):e101745. doi: 10.1371/journal.pone.0101745.
    1. Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL) instrument. Qual. Life Res. Int. J. Qual. Life Asp. Treat. Care Rehabil. 1994;3(5):329–338. doi: 10.1007/BF00451725.
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2009:S1–130. 10.1038/ki.2009.188.
    1. Vieth R. Vitamin D toxicity, policy, and science. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2007;22(Suppl 2):V64–V68. doi: 10.1359/jbmr.07s221.
    1. Jean G, Souberbielle J-C, Lechevallier S, Chazot C. Kinetics of serum 25-hydroxyvitamin D in haemodialysis patients treated with monthly oral cholecalciferol. Clin. Kidney J. 2015;8(4):388–392. doi: 10.1093/ckj/sfv052.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅